David John Porteous

Last updated

David John Porteous
OBE
Professor David Porteous.jpg
Born (1954-07-03) 3 July 1954 (age 70)
Aberdeen
Nationality Scottish
Alma mater University of Edinburgh
Known for Research on Human Genetics, Gene Therapy, Psychiatric genetics, and Population genetics.
SpouseRosie Braid (married 1976)
Scientific career
Fields Human Genetics
Institutions University of Edinburgh
Doctoral advisor Henrik Kacser

David John Porteous OBE (born 3 July 1954) is a Scottish geneticist known for work in the field of genetics. He is Professor Emeritus of Genetics at the University of Edinburgh. [1]

Contents

Education

Porteous attended the Aberdeen Grammar School before attending the University of Edinburgh as an undergraduate (1971–1975) specialising in genetics and a PhD (1975–1978) in metabolic control analysis (now known as systems biology), under the supervision of Dr Henrik Kacser.

Professional life

Porteous has contributed to research projects in cystic fibrosis gene therapy [2] [3] [4] and the first clinical trial of gene therapy in Scotland. [5] In 2001, his group joined with researchers at Imperial College London and University of Oxford to form the UK Cystic Fibrosis Gene Therapy Consortium. [6]

Porteous has contributed to research projects in psychiatric genetics. In collaboration with University of Edinburgh Professors of Psychiatry Douglas Blackwood [7] and Andrew M. McIntosh, he identified genetic risk factors for major mental illness, most notably DISC1. [8]

In 1999, Porteous initiated a population genetics research programme in Scotland called Generation Scotland, a family- and population-based study of genetic and environmental determinants of health and wellbeing. [9]

Porteous was scientific advisor to the House of Commons of the United Kingdom Science, Innovation and Technology Select Committee (1999) that led to the establishment of the United Kingdom Human Genetics Commission (2001-2012).

Awards

Prizes

References

  1. ↑ "Professor David Porteous". The University of Edinburgh. Retrieved 5 April 2025.
  2. ↑ Dorin, JR; Dickinson, P; Alton, EW; Smith, SN; Geddes, DM; Stevenson, BJ; Wimber, KL; Fleming, S; Clarke, AR; Hooper, ML; Anderson, L; Beddington, RSP; Porteous, DJ (1992). "Cystic fibrosis in the mouse by targeted insertional mutagenesis". Nature. 359 (6392): 211–215. Bibcode:1992Natur.359..211D. doi: 10.1038/359211a0 . hdl: 20.500.11820/b96f227d-dde9-466f-9c17-819c53111aa4 . PMID   1382232.
  3. ↑ Alton, EWFW; Middleton, PG; Caplen, PK; Smith, SN; Steel, DM; Munkonge, BJ; Jeffery, PK; Geddes, SL; Hart, SL; Williamson, R; Fasold, KI; Miller, AD; Dickinson, P; Stevenson, BJ; McLachlan, G; Dorin, JR; Porteous, DJ (1993). "Non–invasive liposome–mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice". Nature Genetics. 3 (2): 135–142. doi:10.1038/ng1093-135. PMID   7504552.
  4. ↑ Caplen, NJ; Alton, EWFW; Middleton, PG; Dorin, J; Stevenson, BJ; Gao, X; Durham, SR; Jeffery, PK; Hodson, ME; Coutelle, C; Huang, L; Porteous, DJ; Williamson, R; Geddes, DM (1995). "Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis". Nature Medicine. 1 (1): 39–46. doi:10.1038/nm0195-39. PMID   7584951.
  5. ↑ Porteous, DJ; Dorin, JR; Davidson-Smith, H; Davidson, H; Stevenson, BJ; Carothers, AD; Wallace, WAH; Moralee, S; Hoenes, C; Kallmeyer, G; Michaelis, U; Naujoks, DK; Ho, L-P; Samways, JM; Imrie, M; Greening, AP; Innes, JA (1997). "Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis". Gene Therapy. 4 (3): 210–218. doi:10.1038/sj.gt.3300390. PMID   9135734.
  6. ↑ Alton, EWFW; Armstrong, DK; Ashby-D, H; Bayfield, KJ; Bilton, D; Bloomfield, EV; Boyd, AC; Brand, J; Buchan, R; Calcedo, R; Carvelli, P; Chan, M; Cheng, SH; Collie, DDS; Cunningham, S; Davidson, HE; Davies, G; Davies, JC; Davies, LA; Dewar, MH; Doherty, A; Donovan, J; Dwyer, N; Elgmati, HI; Featherstone, RF; Gavino, J; Dea-Sorli, S; Geddes, DM; Gibson, JSR; Gill, DR; Greening, AP; Griesenbach, U; Hansell, DM; Harman, K; Higgins, TE; Hodges, SL; Hyde, SC; Hyndman, L; Innes, JA; Jacob, J; Jones, N; Keogh, BF; Limberis, MP; MacLean, AW; Manvell, MC; MCormick, D; McGovern, M; McLachlan, G; Meng, C; Monterp, MA; Milligan, H; Moyce, LJ; Murray, GD; Nicholson, AG; Osadolor, T; Parra-Leiton, J; Porteous, DJ; Pringle, IA; Punch, EK; Pytel, KM; Quittner, AL; Rivellini, G; Saunders, CJ; Scheule, RK; Sheard, S; Simmonds, NJ; Smith, K; Smith, SN; Soussi, N; Soussi, S; Spearing, EJ; Stevenson, BJ; Summer-Jones, SG; Turkkila, M; Ureta, RP; Waller, MD; Wasowicz, MY; Wilson, JM; Wolstenholme-Hogg, P; UK Cystic Fibrosis Gene Therapy Consortium, UK (2015). "Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial". Lancet Respiratory Medicine. 3 (9): 684–691. doi:10.1038/sj.gt.3300390. PMC   4673100 . PMID   26149841.
  7. ↑ "Douglas Blackwood". The University of Edinburgh. Retrieved 5 April 2025.
  8. ↑ Millar, JK; Pickard, BS; Mackie, S; James, R; Christie, S; Buchanan, SR; Malloy, MP; Chubb, JE; Huston, E; Baillie, GS; Thomson, PA; Hill, EV; Brandon, NJ; Rain, J-C; Carmago, LM; Whiting, PJ; Houslay, MD; Blackwood, DHR; Muir, WJ; Porteous, DJ (1993). "DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling". Science. 310 (5751): 135–142. doi:10.1126/science.1112915. PMID   16293762.
  9. ↑ "David Porteous (Emeritus)". The University of Edinburgh. 23 September 2024. Retrieved 5 April 2025.
  10. ↑ "Professor David Porteous". The Academy of Medical Sciences. Retrieved 5 April 2025.
  11. ↑ "Professor David Porteous FRSE". Royal Society of Edinburgh. Retrieved 5 April 2025.
  12. ↑ "New Year honours 2013: the full list". The Guardian. 30 December 2012. Retrieved 5 April 2025.
  13. ↑ "Chancellor's Award winners". The University of Edinburgh. 31 March 2025. Retrieved 5 April 2025.
  14. ↑ "Neurosciences". Fondation Ipsen. Archived from the original on 9 June 2018. Retrieved 5 April 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.